Evidence map›Paper›PMID 41155476›Full record

ArticleInternational journal of molecular sciences2025

Constructing a Prognostic Model for Clear Cell Renal Cell Carcinoma Based on Glycosyltransferase Gene and Verification of Key Gene Identification.

Chong Zhou, Mingzhe Zhou, Yuzhou Luo, Ruohan Jiang, Yushu Hu, Meiqi Zhao, Xu Yan, Shan Xiao, Mengjie Xue, Mengwei Wang and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Chong ZhouLaboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China.
Mingzhe ZhouLaboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China.
Yuzhou LuoLaboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China.
Ruohan JiangLaboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China.
Yushu HuLaboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China.
Meiqi ZhaoLaboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China.
Xu YanLaboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China.
Shan XiaoLaboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China.
Mengjie XueLaboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China.
Mengwei WangLaboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China.
Ping JiangLaboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China.
Yunzhen ZhouLaboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China.
Xien HuangLaboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China.
Donglin SunLaboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China.
Chunlong ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.ORCID 0000-0002-1164-8182
Yan JinLaboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China.ORCID 0000-0001-6282-7095
Nan WuLaboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China.ORCID 0000-0002-7401-4136

Funding

Heilongjiang Province "Double First-Class" Discipline Collaborative Innovation Achievement Nurturing Project LJGXCG2024-P12National Natural Science Foundation of China 82172353Natural Science Foundation of Heilongjiang Province YQ2022H004Natural Science Foundation of Heilongjiang Province ZD2023H002
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive subtype of kidney cancer. This study aimed to construct a prognostic model for ccRCC based on glycosyltransferase genes, which play important roles in cell processes like proliferation, apoptosis. Glycosyltransferase genes were collected from four public databases and analyzed using RNA-seq data with clinical information from three ccRCC datasets. Prognostic models were constructed using eight machine learning algorithms, generating a total of 117 combinatorial algorithm models, and the StepCox[forward]+Ridge model with the highest predictive accuracy (C-index = 0.753) which selected and named the Glycosyltransferases Risk Score (GTRS) model. The GTRS effectively stratified patients into high- and low-risk groups with significantly different overall survival and maintained robust performance across TCGA, CPTAC, and E-MTAB1980 cohorts (AUC > 0.75). High-risk patients exhibited higher tumor mutational burden, immunosuppressive microenvironment, and poorer response to immunotherapy. TYMP and GCNT4 were experimentally validated as key genes, functioning as oncogenic and tumor-suppressive factors. In conclusion, GTRS serves as a reliable prognostic tool for ccRCC and provides mechanistic insights into glycosylation-related tumor progression.

Indexed as

Carcinoma, Renal CellGlycosyltransferasesKidney NeoplasmsAlgorithmsBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansMachine LearningMalePrognosisBiomarkers, TumorGlycosyltransferasesclear cell renal cell carcinomaGCNT4glycosyltransferasemachine learning algorithmsrisk modelTYMP

Identifiers

PMID41155476
PMCPMC12563792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.